StocksFundsScreenerSectorsWatchlists
TNGX

TNGX - Tango Therapeutics, Inc. Stock Price, Fair Value and News

7.61USD+0.14 (+1.87%)Market Closed

Market Summary

TNGX
USD7.61+0.14
Market Closed
1.87%

TNGX Stock Price

View Fullscreen

TNGX RSI Chart

TNGX Valuation

Market Cap

777.8M

Price/Earnings (Trailing)

-7.64

Price/Sales (Trailing)

21.29

EV/EBITDA

-7.47

Price/Free Cashflow

-6.51

TNGX Price/Sales (Trailing)

TNGX Profitability

EBT Margin

-280.92%

Return on Equity

-40.2%

Return on Assets

-25.27%

Free Cashflow Yield

-15.37%

TNGX Fundamentals

TNGX Revenue

Revenue (TTM)

36.5M

Rev. Growth (Yr)

-15.29%

Rev. Growth (Qtr)

-49.39%

TNGX Earnings

Earnings (TTM)

-101.7M

Earnings Growth (Yr)

-5.86%

Earnings Growth (Qtr)

-38.18%

Breaking Down TNGX Revenue

Last 7 days

-0.4%

Last 30 days

-23.9%

Last 90 days

-30.4%

Trailing 12 Months

66.9%

How does TNGX drawdown profile look like?

TNGX Financial Health

Current Ratio

7.54

TNGX Investor Care

Shares Dilution (1Y)

15.90%

Diluted EPS (TTM)

-1.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202324.9M33.7M37.5M36.5M
202236.4M24.0M24.2M24.9M
202118.8M29.9M31.6M37.0M
20200007.7M

Tracking the Latest Insider Buys and Sells of Tango Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
third rock ventures iv, l.p.
sold
-1,950,000
12.00
-162,500
-
Feb 07, 2024
barry douglas
sold
-17,087
12.6198
-1,354
general counsel
Feb 07, 2024
crystal adam
sold
-51,526
12.6198
-4,083
see remarks
Feb 07, 2024
weber barbara
sold
-56,246
12.6198
-4,457
chief executive officer
Feb 07, 2024
beckman daniella
sold
-22,930
12.6198
-1,817
chief financial officer
Feb 06, 2024
barry douglas
sold
-17,864
12.5626
-1,422
general counsel
Feb 06, 2024
crystal adam
sold
-53,868
12.5626
-4,288
see remarks
Feb 06, 2024
weber barbara
sold
-58,805
12.5626
-4,681
chief executive officer
Feb 06, 2024
beckman daniella
sold
-23,969
12.5626
-1,908
chief financial officer
Feb 01, 2024
barry douglas
acquired
-
-
22,859
general counsel

1–10 of 38

Which funds bought or sold TNGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
CWM, LLC
reduced
-33.33
-
-
-%
Apr 05, 2024
GAMMA Investing LLC
reduced
-35.44
-523
405
-%
Apr 04, 2024
Mass General Brigham, Inc
new
-
2,812,280
2,812,280
4.92%
Mar 11, 2024
VANGUARD GROUP INC
added
1.34
-3,608,430
29,494,200
-%
Mar 05, 2024
Fisher Asset Management, LLC
new
-
996,840
996,840
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
682
7,601,130
8,894,460
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-31,181
219,681
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-54.04
-16,230,100
11,007,500
0.25%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
11.05
-3,000
113,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
853,618
853,618
-%

1–10 of 49

Are Funds Buying or Selling TNGX?

Are funds buying TNGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TNGX
No. of Funds

Unveiling Tango Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 08, 2024
southpoint capital advisors lp
4.9%
5,276,699
SC 13G/A
Feb 14, 2024
southpoint capital advisors lp
5.2%
5,276,699
SC 13G/A
Feb 13, 2024
gilead sciences, inc.
-
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Oct 18, 2023
bctg holdings, llc
6.9%
6,988,450
SC 13D/A
Oct 16, 2023
ecor1 capital, llc
13.1%
13,330,736
SC 13G/A
Sep 21, 2023
ecor1 capital, llc
7.7%
7,827,636
SC 13G
Sep 11, 2023
fmr llc
-
0
SC 13G/A
Aug 21, 2023
nextech crossover i gp s.a r.l.
5.4%
5,533,980
SC 13G
Aug 16, 2023
bctg holdings, llc
6.9%
6,988,450
SC 13D/A

Recent SEC filings of Tango Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Apr 08, 2024
SC 13G/A
Major Ownership Report
Mar 18, 2024
10-K
Annual Report
Mar 18, 2024
8-K
Current Report
Mar 18, 2024
S-8
Employee Benefits Plan
Feb 21, 2024
144
Notice of Insider Sale Intent
Feb 21, 2024
4
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
4
Insider Trading

Peers (Alternatives to Tango Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.9B
6.8B
-3.12% -31.23%
-8.67
5.97
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
3.75% -25.01%
-43.53
10.48
76.23% 61.08%
17.3B
2.4B
7.34% -6.67%
102.9
7.13
15.42% 18.43%
12.3B
3.7B
-7.42% -25.71%
20.64
3.34
8.87% 75.42%
MID-CAP
6.7B
396.6M
-4.72% -30.06%
-12.71
16.95
425.83% 18.94%
5.0B
-
-1.05% 87.09%
-7.64
60.35
54.84% -34.79%
3.4B
270.6M
3.56% 12.92%
-14.23
12.58
440.80% -27.84%
3.2B
240.7M
-9.88% -9.91%
-10.74
13.24
-1.03% -92.09%
2.9B
726.4M
-12.76% -4.96%
-46.86
3.95
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-2.35% -9.86%
26.11
4.68
85.90% -14.05%
604.6M
983.7M
-14.62% -52.21%
-1.11
0.61
-50.36% 17.16%
419.2M
881.7K
-10.39% 387.20%
-9.4
466.16
-77.61% -5.33%
274.8M
4.9M
2.17% 32.43%
-2.03
56.47
-54.97% 51.72%
7.0M
2.1M
72.41% 90.48%
-0.26
2.14
-13.45% 66.37%

Tango Therapeutics, Inc. News

Latest updates
Defense World57 minutes ago

Tango Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q2
Revenue-49.4%5,431,00010,732,00014,598,0005,766,0006,411,0006,920,0005,771,0005,758,0005,716,0006,787,00018,153,0006,386,000271,0005,064,000
Operating Expenses11.2%40,444,50036,358,00037,845,00036,052,00036,978,00036,843,00030,973,00031,137,00027,700,00026,356,00022,709,00018,467,00018,079,00013,507,000
  S&GA Expenses-1.1%9,105,5009,209,0009,174,0008,013,0007,887,0008,099,0007,232,0006,807,0006,066,0004,433,0003,630,0003,467,000303,4332,378,000
  R&D Expenses15.4%31,339,00027,149,00028,671,00028,039,00029,091,00028,744,00023,741,00024,330,00021,634,00021,923,00019,079,00015,000,00015,063,00011,129,000
EBITDA Margin-4.5%-2.61-2.50-2.91-4.18-4.23-4.08-3.73-1.91-1.53-0.27-0.53-1.05-6.68-
Interest Expenses-100.0%-1,872,0001,450,0001,061,000591,000350,000297,000218,000196,00091,000104,000104,000--
Income Taxes-43.5%13,00023,00064,000-51,000-3,000-185,00062,000-21,00074,0003,432-
Earnings Before Taxes-38.1%-30,716,000-22,240,000-20,646,000--29,009,000-29,050,000-24,855,000-25,208,000-21,869,000-19,528,000-4,514,000-12,032,00026,685,818-8,392,000
EBT Margin-4.4%-2.81-2.69-3.07-4.35-4.35-4.18-3.81-1.95-1.56-0.30-0.56-1.09-6.79-
Net Income-38.2%-30,763,000-22,263,000-20,710,000-28,008,000-29,060,000-29,050,000-24,858,000-25,208,000-22,046,000-19,590,000-4,493,000-12,106,000-8,864,000-8,392,000
Net Income Margin-4.4%-2.79-2.67-3.17-4.46-4.35-4.19-3.82-1.96-1.57-1.43-1.75-2.99-6.79-
Free Cashflow11.1%-27,693,000-31,151,000-25,137,000-35,527,000-29,307,000-22,890,000-33,349,000-31,226,000-17,598,000-22,268,000-7,720,000-13,778,000-9,606,071-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-6.0%40342837940443646444847250053021716820716856.00
  Current Assets-6.6%3473713213433754024364614925162021.001942.0042.00
    Cash Equivalents13.4%66.0059.0066.0057.0060.0010010510014320551.001.0028.002.0023.00
  Net PPE-3.4%10.0010.0011.0011.0011.0011.008.007.005.005.004.00-4.00-3.00
Liabilities-1.4%1491521661771871911501511551651621661696.0048.00
  Current Liabilities5.8%46.0043.0054.0054.0056.0051.0045.0039.0041.0042.0037.000.0041.000.0026.00
Shareholder's Equity-8.5%25327721322724927329932034536555.0058.0039.0047.008.00
  Retained Earnings-9.0%-371-340-318-297-269-240-211-186-161-139-119-0.36-103-0.05-51.13
  Additional Paid-In Capital1.0%6246185335275235185145105075058.005.001425.003.00
Shares Outstanding0.3%10210288.0088.0088.0088.0088.0088.0088.0070.0049.0042.0040.0029.00-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations11.8%-27.47-31.13-24.47-34.91-28.27-19.61-31.54-29.66-16.90-21.49-7.52-13.61-9.15-0.09--
  Share Based Compensation0.4%5.005.005.004.004.004.003.003.002.003.001.001.001.000.00--
Cashflow From Investing159.7%34.00-56.6633.0032.00-12.6015.0035.00-11.72-45.21-152-6.6221.00-29.60-166--
Cashflow From Financing-98.2%1.0080.001.000.001.000.001.000.00-0.12328-0.7530.00-0.03168--

TNGX Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Collaboration revenue$ 36,527$ 24,860
Operating expenses:  
Research and development115,198105,906
General and administrative35,50230,025
Total operating expenses150,700135,931
Loss from operations(114,173)(111,071)
Other income :  
Interest income6,6191,456
Other income , net5,9441,493
Total other income, net12,5632,949
Loss before income taxes(101,610)(108,122)
Provision for income taxes(134)(54)
Net loss$ (101,744)$ (108,176)
Net loss per common share - basic$ (1.08)$ (1.23)
Net loss per common share - diluted$ (1.08)$ (1.23)
Weighted-average common stock outstanding - basic94,572,44887,820,037
Weighted-average common stock outstanding - diluted94,572,44887,820,037
Net Income (Loss)$ (101,744)$ (108,176)
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities3,891(2,940)
Comprehensive loss(97,853)(111,116)
Collaboration Revenue [Member]  
Collaboration revenue31,527$ 24,860
License Revenue [Member]  
Collaboration revenue$ 5,000 

TNGX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 66,385$ 59,968
Marketable securities270,500306,165
Accounts receivable 2,000
Restricted cash856567
Prepaid expenses and other current assets8,7976,572
Total current assets346,538375,272
Property and equipment, net9,90810,884
Operating lease right-of-use assets43,50846,886
Restricted cash, net of current portion2,5673,423
Other assets465
Total assets402,567436,470
Current liabilities:  
Accounts payable2,7854,453
Accrued expenses and other current liabilities15,40117,495
Operating lease liabilities2,0821,770
Deferred revenue25,67031,792
Income tax payable 35
Total current liabilities45,93855,545
Operating lease liabilities, net of current portion36,83839,361
Deferred revenue, net of current portion66,68392,088
Total liabilities149,459186,994
Commitments and contingencies (Note 8)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022, respectively
Stockholders' equity:  
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 102,202,759 and 88,179,374 shares issued and outstanding as of December 31, 2023 and 2022, respectively10288
Additional paid-in capital624,076522,605
Accumulated other comprehensive income (loss)186(3,705)
Accumulated deficit(371,256)(269,512)
Total stockholders' equity253,108249,476
Total liabilities and stockholders' equity$ 402,567$ 436,470
TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEtangotx.com
 INDUSTRYBiotechnology
 EMPLOYEES110

Tango Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Tango Therapeutics, Inc.? What does TNGX stand for in stocks?

TNGX is the stock ticker symbol of Tango Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tango Therapeutics, Inc. (TNGX)?

As of Thu Apr 11 2024, market cap of Tango Therapeutics, Inc. is 777.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNGX stock?

You can check TNGX's fair value in chart for subscribers.

What is the fair value of TNGX stock?

You can check TNGX's fair value in chart for subscribers. The fair value of Tango Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tango Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tango Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNGX is over valued or under valued. Whether Tango Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tango Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNGX.

What is Tango Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, TNGX's PE ratio (Price to Earnings) is -7.64 and Price to Sales (PS) ratio is 21.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNGX PE ratio will change depending on the future growth rate expectations of investors.